Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier
|
|
- Beverly Dean
- 6 years ago
- Views:
Transcription
1 Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Choroideremia OMIM number for disease Disease alternative names please provide any alternative names you wish listed Disease please provide a brief description of the disease characteristics Disease - mode of inheritance Gene name(s) OMIM number for gene(s) Gene alternative names please provide any alternative names you wish listed Gene description(s) (including number of amplicons) Mutational spectrum for which you test including details of known common mutations. Tapetochoroidal dystrophy Choroidal sclerosis Choroideremia is an X-linked ocular disorder that leads to the degeneration of the choriocapillaris, retinal pigment epithelium, and the retinal photoreceptor of the eye. Affected males suffer progressive loss of vision (reduction of central vision, constriction of visual fields, night blindness) beginning at an early age, and the choroid and retina undergo complete atrophy. Heterozygous females show little or no visual defect although many (not all) show funduscopic changes. X-Linked Recessive CHM gene, which encodes Rab escort protein-1 (REP1) CHM Rab escort protein 1 REP1 CHM is the only gene known to be associated with choroideremia. It has 15 coding exons across bp of genomic DNA. It has a transcript length of 2,115 bps which encodes for the 653 amino acid Rab escort protein 1 (REP1) protein. This gene is amplified in 15 amplicons (UKGTN MOLU Band D). There are no founder/common mutations. Our screen detects point mutations and small insertion deletion variants. Whole exon deletions can be detected in males but not in females. Technical Method (s) Validation Process Note: please explain how this test has been validated for use in your laboratory Bi-directional fluorescent Sanger sequencing for point mutations and indels. Multiplex PCR for exonic deletions in males. There are no reference materials available to act as validation controls. A series of patients ascertained through research testing have been repeat tested in developing the diagnostic system. We have screened 36 patients for the CHM gene. We found a total of 25 mutations. All mutations found were confirmed with two fresh dilutions. 1
2 Are you providing this test already? If yes, how many reports have you produced? Please give the number of mutation positive/negative samples you have reported For how long have you been providing this service? Is there specialised local clinical/research expertise for this disease? Are you testing for other genes/diseases closely allied to this one? Please give details Your Current Activity If applicable - How many tests do you currently provide annually in your laboratory? Your Capacity if Gene Dossier approved How many tests will you be able to provide annually in your laboratory if this gene dossier is approved and recommended for NHS funding? Based on experience how many tests will be required nationally (UK wide)? National Activity (England, Scotland, Wales & Northern Ireland) If your laboratory is unable to provide the full national need please could you provide information on how the national requirement may be met. For example, are you aware of any other labs (UKGTN members or otherwise) offering this test to NHS patients on a local area basis only? This question has been included In order to gauge if there could be any issues in equity of access for NHS patients. It is appreciated that some laboratories may not be able to answer this question. If this is the case please write unknown. Yes Number of reports issued: 36 Number of reports mutation positive: 25 Number of reports mutation negative:11 2 Years Yes No Please provide details Close links are retained with the Regional Clinical Genetics Service, Manchester Royal Eye Hospital and Moorfields Eye Hospital. We currently offer testing for a wide range of ophthalmic genetic disorders. X-linked and dominant retinitis pigmentosa (gene dossiers accepted), Best disease, macular dystrophy, Leber congenital amaurosis (gene dossiers pending). See above we have to date tested 36 index cases in 24 months. We anticipate a workload of up to 40 index cases pa and a further 20 reflex tests (see below). We can meet this capacity in house. We are currently only receiving samples from two centres (Manchester and Moorfield s). We would expect this to rise if the dossier is accepted. Based upon current demand we anticipate perhaps 40 index cases pa. This will lead to reflex testing for up to 20 relatives pa. This is solely a linkage based service. Consequently we are the only laboratory offering a mutation scanning service. We feel we can continue to meet the national need. 2
3 Epidemiology Estimated prevalence of disease in the general UK population Estimated gene frequency (Carrier frequency or allele frequency) Estimated penetrance Prevalence is estimated to be 1:50,000. This estimation is supported by the assumption that if the prevalence of RP is 1:3500, and about 6% of individuals diagnosed with RP-related disorders actually have CHM [Heckenlively 1991], it is likely that approximately 1:58,000 individuals have CHM. Heckenlively JR. Choroideremia. In: Heckenlively JR, Arden GB (eds) Principles and Practice of Clinical Electrophysiology of Vision. Mosby Year Book, St. Louis, pp Whilst most affected individuals are male this disorder can affect females. Therefore it is not possible to accurately estimate carrier frequencies from the disease prevalence figures (above). The penetrance is high (100%) in males but can vary in females due to X-inactivation. Target Population Description of the population to which this test will apply (i.e. description of the population as defined by the minimum criteria listed in the testing criteria) Estimated prevalence of disease in the target population The target population is defined by the choroideremia phenotype, ie. only cases with a high index of suspicion (ascertained by clinical geneticists or collaborating ophthalmologists) and a high probability of carrying a CHM mutation are offered testing. Reflex testing (carrier and predictive) will be made available to family members in the context of appropriate genetic counselling. The test will be available to all UK inhabitants. Only individuals with a high prior likelihood of carrying a mutation (ie affected by choroideremia) will be tested. In the first two years of screening we identified causative mutations in 25 out of 36 index cases referred. Intended Use (Please use the questions in Annex A to inform your answers) Please tick the relevant clinical purpose of testing YES NO Diagnosis Treatment Prognosis & Management Presymptomatic testing Risk Assessment for family members Risk Assessment prenatal testing (see text) 3
4 Test Characteristics An alytical sensitivity and specificity This should be based on your own laboratory data for the specific test being applied for or the analytical sensitivity and specificity of the method/technique to be used in the case of a test yet to be set up. Clinical sensitivity and specificity of test in target population The clinical sensitivity of a test is the probability of a positive test result when disease is known to be present; the clinical specificity is the probability of a negative test result when disease is known to be absent. The denominator in this case is the number with the disease (for sensitivity) or the number without disease (for specificity) Clinical validity (positive and negative predictive value in the target population) The clinical validity of a genetic test is a measure of how well the test predicts the presence or absence of the phenotype, clinical disease or predisposition. It is measured by its positive predictive value (the probability of getting the disease given a positive test) and negative predictive value (the probability of not getting the disease given a negative test). Testing pathway Please include your testing strategy if more than one gene will be tested and data on the expected proportions of positive results for each part of the process. Please illustrate this with a flow diagram. This can be added to the document as a separate sheet if necessary. On the basis of re-sequencing of positive controls (and experiences with other services in the lab) we estimate that the analytical sensitivity and specificity of the techniques used (Sanger sequencing and multiplex PCR) will be greater than 98%. To date no other gene has been implicated in this disease. In our cohort a pathogenic variant has been found in 90% of males with a strong clinical suspicion of choroideremia So far all confirmed CHM mutations have been clearly pathogenic (frame-shift, nonsense, splice site) and interpretation has been straightforward. Missense changes of unknown clinical significance are rare (only one so far identified in our cohort). Given the very low number of UVs and the high penetrance in males the positive predictive value in males is almost 100%. The vast majority of females remain asymptomatic - there is a low positive predictive value in females. Similarly the negative predictive value in a family with a known mutation will be 100% in males. This is a single gene test. 4
5 Clinical utility of test in target population (Please refer to Appendix A) Please provide a description of the clinical care pathway. Choroideremia (CHM) is a severe form of retinal dystrophy. Males with the disease present in the first two decades of life and are significantly disabled by the condition during adulthood, however it can be challenging to distinguish CHM from other retinal dystrophies. Genetic testing for choroideremia has a large impact on the families in establishing the mode of inheritance and identifying or excluding carrier status in women (carriers often have a normal fundus in adult-hood). How will the test add to the management of the patient or alter clinical outcome? What impact will this test have on the NHS i.e. by removing the need for alternative management and/or investigations for this clinical population? Please provide evidence from your own service. The implications of CHM are similar to other X-linked disorders: Asymptomatic young females - in particular those with experience of their fathers/brothers with the disease, are often anxious to know their carrier status. Since this cannot be provided with 100% accuracy from clinical testing, carrier testing is often sought by these females. a. Asymptomatic young females, in whom carrier status is excluded are able to be discharged from follow-up. b. Females carrying a mutation may be offered PND. Asymptomatic males a. The age at which males should be tested is debatable however, families are often keen to ensure that boys are diagnosed early since this impacts upon education, training, life choices (e.g. career choices) and management. For this reason examination, or genetic testing, under the age of 5 may be requested and is considered. b. Males who have been reassured on clinical grounds are often anxious to have genetic confirmation later in life in order to demonstrate that they do not carry mutations. Symptomatic males Molecular confirmation has a positive impact on coping with this debilitating disease. CHM is associated with severe early onset visual disability and blindness secondary to retinal degeneration. The condition is therefore associated with a significant and progressive disability in the context of normal general health that is also progressive. The condition is X linked. Genetic counselling: Genetic testing for CHM mutations will provide a precise molecular diagnosis in over 95% of cases. This provides clearer information regarding carrier status (not all carriers are distinguishable clinically) and hence will provide choices (eg PND) that would not otherwise be available. This test will impact significantly on a significant number of families by offering options (carrier, pre-symptomatic and prenatal testing) where this has previously not been possible. It will benefit families in whom one or more individuals have a clinical diagnosis of choroideremia. 5
6 What are the consequences of not doing this genetic test. Commissioners have asked for specific information to support introduction of tests. Utility of test in the NHS In a couple of sentences explain the utility of this test for the disease(s) Is there an alternative means of diagnosis or prediction that does not involve molecular diagnosis? If so (and in particular if there is a biochemical test) please state the added advantage of the molecular test Please describe any specific ethical, legal or social issues with this particular test? Denying this testing will severely limit the reproductive choices of patients thereby increasing significantly the emotional burden of the disease. Female carrier not being identified leading to males being born with severe visual impairments. This test identifies a severe inherited retinal dystrophy. It will make possible carrier, pre-symptomatic and first trimester prenatal diagnosis. Affected individuals are first identified by characteristic changes in the fundus on retinal examination. However this is not a reliable carrier test in females. None known 6
7 UKGTN Testing criteria Name of Disease(s): CHOROIDEREMIA; CHM (303100) Name of gene(s): choroideremia (Rab escort protein 1); CHM (300390) Patient name: Patient postcode: Date of birth: NHS number: Name of referrer: Title/Position: Lab ID: Referrals will only be accepted from one of the following: Referrer Consultant Clinical Geneticist Consultant Ophthalmologist Tick if this refers to you. Minimum criteria required for testing to be appropriate as stated in the Gene Dossier: Criteria Males with progressive loss of vision (reduction of central vision, constriction of visual fields, night blindness) beginning at an early age AND Extinguished or severely reduced scotopic and photopic electroretinogram (ERG) AND Characteristic fundus appearance (choroid and retina undergo complete atrophy) OR At risk relatives in family with known mutation Tick if this patient meets criteria If the sample does not fulfil the clinical criteria or you are not one of the specified types of referrer and you still feel that testing should be performed please contact the laboratory to discuss testing of the sample. 7
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Leber congenital amaurosis OMIM number for disease 204000 Disease alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Epileptic encephalopathy, early infantile 4. OMIM number for disease 612164 Disease
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name HEMOCHROMATOSIS, TYPE 4; HFE4 OMIM number for disease #606069 Disease alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Genetic Causes of Hypothyroidism 1. Loss of function mutations in TSHR cause thyroid
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Parkinson disease 8, automsomal dominant OMIM number for disease 607060 Disease
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 231300 Disease alternative names Please provide any alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names Osteogenesis Imperfecta
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Loeys-Dietz Syndrome OMIM number for disease 609192; 608967; 610380; 610168 Disease
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 147920 Disease alternative names Please provide any alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Cambridge RGC Approved: September 2012
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Exeter RGC Approved: Sept 2013 1. Disorder/condition
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease Disease alternative names please provide any alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) Glucocorticoid-remediable
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Polycystic Kidney Disease, Autosomal Dominant OMIM number for disease 173900 Disease
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 312060 Disease alternative names please provide any alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Birmingham RGC Approved: September 2012
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: London North East RGC GOSH Approved: September
More informationApplication to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form
Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form Disease: Gene: Cystic Fibrosis (CF) (carrier testing in reproductive
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Manchester RGC Approved: September 2013
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationSubmitting Laboratory: London NE RGC GOSH
Submitting laboratory: London NE RGC GOSH 1. Disorder/condition approved name (please provide UK spelling if different from US) and symbol as published on the OMIM database (alternative names will be listed
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: London North East RGC GOSH Approved: September
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Cardiff SAS Porphyria Approved: Sept
More informationUKGTN Testing Criteria
UKGTN Testing Criteria Approved name and symbol of disease/condition(s): Retinal Degeneration panel test Approved name and symbol of gene(s): a panel of 105 genes, variants of which have been shown to
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Submitting laboratory: Bristol RGC 1. Disorder/condition approved name and symbol as published on the OMIM database (alternative
More informationCorporate Medical Policy
Corporate Medical Policy Voretigene Neparvovec-rzyl (Luxturna) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: voretigene_neparvovec_rzyl_luxturna 1/2018 N/A 6/2018 2/2018 Description
More informationINDEX. Genetics. French poodle progressive rod-cone degeneration,
INDEX Acuity in Stargardt's macular dystrophy, 25-34 ADRP (Autosomal dominant retinitis pigmentosa), see Retinitis pigmentosa and Genetics afgf, 294, 296 Age-related maculopathy, see Macular degeneration
More informationLab Activity Report: Mendelian Genetics - Genetic Disorders
Name Date Period Lab Activity Report: Mendelian Genetics - Genetic Disorders Background: Sometimes genetic disorders are caused by mutations to normal genes. When the mutation has been in the population
More informationLUXTURNA (voretigene neparovec-rzyl)
LUXTURNA (voretigene neparovec-rzyl) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationSymptoms, causes and treatment options of different IRDs
Symptoms, causes and treatment options of different IRDs While all IRDs affect the retina and visual function, the symptoms, onset, progression and cause of each varies. Here, we will give an overview
More informationNGS Types of gene dossier applications UKGTN can evaluate
NGS Types of gene dossier applications UKGTN can evaluate Jo Whittaker on behalf of the Genetic Test Evaluation Working Group & UKGTN Project team NGS used in a number of ways Replacement technology for
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationCorporate Medical Policy
Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationHow many disease-causing variants in a normal person? Matthew Hurles
How many disease-causing variants in a normal person? Matthew Hurles Summary What is in a genome? What is normal? Depends on age What is a disease-causing variant? Different classes of variation Final
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Leeds RGC 1. Disorder/condition approved name (please provide UK spelling if different
More informationUK National Screening Committee. Screening for Fragile X Syndrome in Pregnancy. 18 June 2015
UK National Screening Committee Screening for Fragile X Syndrome in Pregnancy 18 June 2015 Aim 1. This document provides background on the item addressing antenatal screening for Fragile X syndrome. Current
More informationLesson Overview. Human Chromosomes. Lesson Overview. Human Chromosomes
Lesson Overview Karyotypes A genome is the full set of genetic information that an organism carries in its DNA. A study of any genome starts with chromosomes, the bundles of DNA and protein found in the
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationC horoideraemia is an X linked, recessively inherited,
658 CLINICAL SCIENCE Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia M Flynn Roberts, G A Fishman, D K Roberts, J R Heckenlively, R G Weleber, R J Anderson,
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Sheffield RGC 1. Disorder/condition approved name (please provide UK spelling
More informationRPE65-associated Leber Congenital Amaurosis
RPE65-associated Leber Congenital Amaurosis Brian Privett, MD, Edwin M. Stone, MD, PhD February 16, 2010 Chief Complaint: Poor fixation at 4 months of age History of Present Illness: This 7 year old female
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: 1. Disease/condition approved name and
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationIdentification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome
Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome L.H. Cao 1, B.H. Kuang 2, C. Chen 1, C. Hu 2, Z. Sun 1, H. Chen 2, S.S. Wang
More informationUnravelling the genetic basis of simplex Retinitis Pigmentosa cases
SUPPLEMENTARY INFORMATION Unravelling the genetic basis simplex Retinitis Pigmentosa cases Nereida Bravo-Gil 1,2#, María González-del Pozo 1,2#, Marta Martín-Sánchez 1, Cristina Méndez-Vidal 1,2, Enrique
More informationAdvances in assessing and managing vision impairment
Advances in assessing and managing vision impairment John Grigg Associate Professor and Head Discipline of Ophthalmology Consultant Ophthalmologist Sydney Eye Hospital and The Children s Hospital at Westmead
More informationGenetic Counselling in relation to genetic testing
Genetic Counselling in relation to genetic testing Dr Julie Vogt Consultant Geneticist West Midlands Regional Genetics Service September 2016 Disclosures for Research Support/P.I. Employee Consultant Major
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Highly Specialised Technology Evaluation
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Highly Specialised Technology Evaluation Drisapersen for treating Duchenne muscular Draft scope (pre-referral) Draft remit/evaluation objective
More informationKamron N Khan PhD, FRCOphth [1-3], Keren Carss [5], F. Lucy Raymond [5], Farrah Islam
Title: Vitamin A deficiency - there's more to it than meets the eye. Kamron N Khan PhD, FRCOphth [1-3], Keren Carss [5], F. Lucy Raymond [5], Farrah Islam FCPS, FRCS [2], Anthony T Moore FRCS, FRCOphth
More informationBenefits and pitfalls of new genetic tests
Benefits and pitfalls of new genetic tests Amanda Krause Division of Human Genetics, NHLS and University of the Witwatersrand Definition of Genetic Testing the analysis of human DNA, RNA, chromosomes,
More informationAn Introduction to mitochondrial disease.
9 th September 2017 An Introduction to mitochondrial disease. Dr Andy Schaefer Consultant Neurologist and Clinical Lead NHS Highly Specialised Rare Mitochondrial Disease Service and Wellcome Trust Centre
More informationClinical Spectrum and Genetic Mechanism of GLUT1-DS. Yasushi ITO (Tokyo Women s Medical University, Japan)
Clinical Spectrum and Genetic Mechanism of GLUT1-DS Yasushi ITO (Tokyo Women s Medical University, Japan) Glucose transporter type 1 (GLUT1) deficiency syndrome Mutation in the SLC2A1 / GLUT1 gene Deficiency
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Bristol RGC Approved: Sept 2013 1. Disorder/condition
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More informationVisual Conditions in Infants and Toddlers
Visual Conditions and Functional Vision: Early Intervention Issues Visual Conditions in Infants and Toddlers Brief Overview of Childhood Visual Disorders Hatton, D.D. (2003). Brief overview of childhood
More informationPhenotype Report. Num. Positions Not Called (Missing data) Num. Variants Assessed
Report Date: August 19, 2015 Software Annotation Version: 8 Report Name: NA12144 NW European Genome : NA12144_S1 Sequencing Provider: Illumina Sequencing Type: Exome : Retinitis Pigmentosa Description:
More informationGENETIC TESTING FOR RETINAL DISEASES. A resource for the inherited retinal disease community
GENETIC TESTING FOR RETINAL DISEASES A resource for the inherited retinal disease community WHAT IS GENETIC TESTING? 2 Genetic testing is a process that identifies changes, called mutations, in a person
More informationNGS panels in clinical diagnostics: Utrecht experience. Van Gijn ME PhD Genome Diagnostics UMCUtrecht
NGS panels in clinical diagnostics: Utrecht experience Van Gijn ME PhD Genome Diagnostics UMCUtrecht 93 Gene panels UMC Utrecht Cardiovascular disease (CAR) (5 panels) Epilepsy (EPI) (11 panels) Hereditary
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationDeciphering Developmental Disorders (DDD) DDG2P
Deciphering Developmental Disorders (DDD) DDG2P David FitzPatrick MRC Human Genetics Unit, University of Edinburgh Deciphering Developmental Disorders objectives research understand genetics of DD translation
More informationMen s consent to the use and storage of sperm or embryos for surrogacy
HFEA MSG form Men s consent to the use and storage of sperm or embryos for surrogacy About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent
More informationHydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening
linical Guidelines Hydroxychloroquine and hloroquine Retinopathy: Recommendations on Screening February 2018 - Review date: February 2021 Executive Summary Recent data have highlighted that hydroxychloroquine
More informationApplying structure-function to solve clinical cases
Applying structure-function to solve clinical cases Professor Michael Kalloniatis Centre for Eye Health, and, School of Optometry and Vision Science Acknowledgements Some material prepared by Nayuta Yoshioka
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: London NE RGC GOSH 1. Disorder/condition approved name (please provide UK spelling
More informationOptometric Cataract Refined Referral
Optometric Cataract Refined Referral Guidance Notes for Optometrists Version Control: v1: April 2013 v2: August 2015 REFINED CATARACT REFERRAL PATHWAY GUIDANCE FOR OPTOMETRISTS Background Approximately
More informationGenetics and Genomics: Applications to Developmental Disability
Tuesday, 12:30 2:00, B1 Objective: Genetics and Genomics: Applications to Developmental Disability Helga Toriello 616-234-2712 toriello@msu.edu Identify advances in clinical assessment and management of
More informationCentoXome FUTURE'S KNOWLEDGE APPLIED TODAY
CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For certain patients the combination of symptoms does not allow
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process
Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY
More informationGenetics and the Macular Dystrophies. George Anadiotis D.O. Medical Director Clinical and Biochemical Genetics Randall Children s Hospital
Genetics and the Macular Dystrophies George Anadiotis D.O. Medical Director Clinical and Biochemical Genetics Randall Children s Hospital Stargardt disease Best Vitelliform Macular Dystrophy North Carolina
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationMuscular Dystrophy. Biol 405 Molecular Medicine
Muscular Dystrophy Biol 405 Molecular Medicine Duchenne muscular dystrophy Duchenne muscular dystrophy is a neuromuscular disease that occurs in ~ 1/3,500 male births. The disease causes developmental
More informationUnderstanding genetics, mutation and other details. Stanley F. Nelson, MD 6/29/18
Understanding genetics, mutation and other details Stanley F. Nelson, MD 6/29/18 1 6 11 16 21 Duchenne muscular dystrophy 26 31 36 41 46 51 56 61 66 71 76 81 86 91 96 600 500 400 300 200 100 0 Duchenne/Becker
More informationThalassaemia and Abnormal Haemoglobins in Pregnancy
1. Purpose Thalassaemias and abnormal haemoglobins are detected in approximately 4% of patients of reproductive age attending the Women's. In almost half of these cases, the abnormality is not evident
More informationCentoXome FUTURE'S KNOWLEDGE APPLIED TODAY
CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For some patients, the combination of symptoms does not allow
More informationForm 3. Template for a full review process for a condition being considered for addition to the newborn/child screening panel
Form 3. Template for a full review process for a condition being considered for addition to the newborn/child screening panel **Note: please specify the basis for each answer and rely on published evidence
More informationA guide to understanding variant classification
White paper A guide to understanding variant classification In a diagnostic setting, variant classification forms the basis for clinical judgment, making proper classification of variants critical to your
More informationGenetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report
Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report Roshanak Jazayeri, MD, PhD Assistant Professor of Medical Genetics Faculty of Medicine, Alborz University of Medical Sciences
More informationThe effect of intravitreal bevacizumab in a rare case of retinal dystrophy with secondary cystoid macular edema
Romanian Journal of Ophthalmology, Volume 61, Issue 2, April-June 2017. pp:123-127 CASE REPORT The effect of intravitreal bevacizumab in a rare case of retinal dystrophy with secondary cystoid macular
More informationHEREDITARY HEMOCHROMATOSIS
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEREDITARY HEMOCHROMATOSIS Policy Number: PDS - 020 Effective Date: January 1, 2015
More informationSALSA MLPA KIT P060-B2 SMA
SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the
More informationRETINITIS PIGMENTOSA A RARE GENETICAL DISORDER
RETINITIS PIGMENTOSA A RARE GENETICAL DISORDER Retinitis pigmentosa (RP) is a group of inherited disorders affecting 1 in 3000-7000 people and characterized by abnormalities of the photoreceptors (rods
More informationHow the eye works. Causes of retinitis pigmentosa
Retinitis pigmentosa Retinitis pigmentosa (RP) is the name given to a diverse group of inherited eye disorders which affect a part of the eye called the retina. RP causes permanent changes to your vision
More informationSupplementary Online Content
Supplementary Online Content Ku CA, Hull S, Arno G, et al. Detailed clinical phenotype and molecular genetic findings in CLN3-associated isolated retinal degeneration. JAMA Ophthalmol. Published online
More informationINHERITED RETINAL DISEASE. The Rod/Cone Dichotomy. Case History/Entrance Skills. Health Assessment 9/4/18. Hereditary Retinal Diseases Epidemiology
Hereditary Retinal Diseases Epidemiology INHERITED RETINAL DISEASE Blair Lonsberry, MS, OD, MEd., FAAO Professor of Optometry Pacific University College of Optometry blonsberry@pacificu.edu HRDs affect
More informationUKGTN Testing Criteria
UKGTN Testing Criteria Test name: Inherited Bone Marrow Failure Syndromes 44 Gene Panel Approved name disorder/(s): See Appendix 1 Approved name (s): See Appendix 1 (s): (s): Patient name: Patient postcode:
More informationUKGTN Testing Criteria
Test name: Neonatal Diabetes 22 Gene Panel UKGTN Testing Criteria Approved name and symbol of disorder/condition(s): See Appendix 1 Approved name and symbol of gene(s): See Appendix 1 number(s): number(s):
More informationMerging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines
Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines Tracy Brandt, Ph.D., FACMG Disclosure I am an employee of GeneDx, Inc., a wholly-owned
More informationIndication criteria for disease: Noonan syndrome [PTPN11, SOS1, RAF1, KRAS]
deutsche gesellschaft für humangenetik e.v. Indication Criteria for Genetic Testing Evaluation of validity and clinical utility german society of human genetics www.gfhev.de Indication criteria for disease:
More informationHappy New Year! Dan Roberts. International Low Vision Support Group NEWSLETTER. This Month. In This Issue
In This Issue 1: This Month 2-4: News 5: A Message to Your Doctor Happy New Year! from Macular Degeneration Support The ILVSG is sponsored by MD Foundation www.eyesight.org 888-633-3937 ILVSG TeleSupport
More informationNovel Heterozygous Mutation in YAP1 in A Family with Isolated Ocular Colobomas
Novel Heterozygous Mutation in YAP1 in A Family with Isolated Ocular Colobomas Julius T. Oatts 1, Sarah Hull 2, Michel Michaelides 2, Gavin Arno 2, Andrew R. Webster 2*, Anthony T. Moore 1,2* 1. Department
More informationMEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG)
Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with
More informationData briefing: Reflex testing for Lynch syndrome in people diagnosed with bowel cancer under the age of 50
Data briefing: Reflex testing for Lynch syndrome in people diagnosed with bowel cancer under the age of 50 Introduction Lynch syndrome is an inherited condition that predisposes individuals to bowel and
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationGenetic counselling in PGD
Genetic counselling in PGD Sérgio Castedo Serviço de Genética Faculdade de Medicina do Porto scastedo@netcabo.pt Disclosure of interests Sérgio Castedo is the CEO of GDPN, a private genetics diagnostic
More information